25.11.2016 1 Dr Christophe Massard SIOG 2016 Milan, 19 NOV 2016 Immunotherapy Hot topics in geriatric oncology • Participation to advisoryboards, speaker or investigator for: Amgen, Astellas, Astra Zeneca, Bayer, Celgene, Genentech, Ipsen, Jansen, Lilly, Novartis, Pfizer, Roche, Sanofi, Orion, MedImmune, New Oncology, DebioPharm • I am a PI of Eli Lilly and Company trial with NOTCH inhibitor • I will not discuss off label use in my presentation • I will discuss investigational use in my presentation Disclosure • Participation to advisoryboards, speaker or investigator for: Amgen, Astellas, Astra Zeneca, Bayer, Celgene, Genentech, Ipsen, Jansen, Lilly, Novartis, Pfizer, Roche, Sanofi, Orion, MedImmune, New Oncology, DebioPharm • I am a PI of Eli Lilly and Company trial with NOTCH inhibitor • I will not discuss off label use in my presentation • I will discuss investigational use in my presentation Disclosure Systemic anti-cancer therapies CHEMOTHERAPY TARGETED THERAPIES IMMUNOTHERAPIES Outline • Background • Immunecheckpoints • Drugs in development • Perspectives
5
Embed
Immunotherapy Disclosure• I willdiscussinvestigationaluse in mypresentation Disclosure Systemic anti-cancer therapies TARGETED THERAPIES CHEMOTHERAPY IMMUNOTHERAPIES Outline •
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
25.11.2016
1
Dr Christophe Massard
SIOG 2016 Milan, 19 NOV 2016
Immunotherapy
Hot topics in geriatric oncology• Participation to advisory boards, speaker or investigator